New drug targets Hard-to-Treat uterine cancer in small trial

NCT ID NCT07139977

Recruiting now Disease control Sponsor: William Bradley Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests a drug called enfortumab vedotin in up to 12 people with advanced endometrial (uterine) cancer that has worsened after standard treatments like immunotherapy. The drug works by targeting a protein on cancer cells to kill them. Researchers will measure how many patients' tumors shrink and monitor for side effects over one year of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin
What this could lead to: If it works, this could offer a new treatment option for people with advanced endometrial cancer that has not responded to other therapies.
What could go wrong: This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

Froedtert Memorial Lutheran Hospital
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.